Related Experiment Video
Updated: Jun 19, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
An Update on Cutaneous Angiosarcoma Diagnosis and Treatment
Elizabeth Richards1, Joshua Schimmel1, Michael Renzi1
1Dr. Richards is from Cooper Medical School of Rowan University, Camden, New Jersey. Dr. Schimmel is from the Department of Dermatology, University of Colorado, Aurora. Dr. Renzi is from Dermatology Consultants, Lexington, Kentucky. Dr. Lawrence is from Cooper Dermatologic Surgery at Marlton, New Jersey.
Cutaneous angiosarcoma (CAS) is a rare cancer, often seen in older men on the head or neck. Early detection through skin exams and multidisciplinary care are key for better outcomes.
Area of Science:
- Oncology
- Dermatology
Background:
- Cutaneous angiosarcoma (CAS) is a rare, aggressive vascular malignancy.
- It predominantly affects White men over 60, presenting as ecchymosis on the head, neck, or scalp.
Purpose of the Study:
- To review the current understanding and management of cutaneous angiosarcoma.
- To emphasize the role of dermatologists in early diagnosis and the importance of multidisciplinary care.
Main Methods:
- Review of existing literature on cutaneous angiosarcoma.
- Discussion of diagnostic and therapeutic strategies.
Main Results:
- Surgery with negative margins is the primary treatment for CAS.
- The role of Mohs micrographic surgery (MMS) is limited to specific cases.
- Dermatologists' heightened awareness and thorough skin examinations are crucial for timely diagnosis.
Conclusions:
- Multidisciplinary care at specialized cancer centers is essential for optimizing outcomes in rare and difficult-to-treat tumors like CAS.
- Further research is needed to establish consensus guidelines for CAS management.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies
There are several types of targeted therapies against...

